Analysis of IL-1ra Gene Polymorphism in Patients with IgA Nephropathy, Henoch-Sch(o)nlein Purpura Nephritis, and Microscopic Polyangiitis

BAO Hao,CHEN Zhaohong,ZHANG Xin,CHEN Huiping,ZENG Caihong,ZHENG Chunxia,ZHANG Jiong,LIU Zhihong,LI Leishi
DOI: https://doi.org/10.3969/j.issn.1006-298x.2007.03.002
2007-01-01
Abstract:Objective:To investigate whether IgA nephropathy(IgAN) or a subgroup of IgAN shares congenerous IL-1ra gene polymorphism with Henoch-Schnlein purpura nephritis (HSPN) and microscopic polyangiitis (MPA). Methodology:DNA was extracted from 200 patients with IgAN, 90 patients with HSPN, 45 patients with MPA and 100 healthy volunteers. The polymorphism of the variable number tandem repeat (VNTR) of IL-1 receptor antagonist (IL-1ra) gene was analyzed using PCR. The clinical and pathological features of IgAN with different genotypes were analyzed. The patients with IgAN were divided into 6 groups according to their clinicopathological manifestations. They were: crescentic (Cres.,16 cases), recurrent gross hematuria (R-GH, 27), mass proteinuria (MP, 21), hypertension(HT, 42), isolated microscopic hematuria (I-H, 5) and asymptomatic abnormal urinalysis (U-ab, 89 cases). The distribution of IL-1ra alleles was compared among different types of IgAN, HSPN, MPA patients and normal controls. Results:There was no significant difference in the allele frequency and carriage rate of IL1RN*2 between patients with IgAN and healthy controls. The patients carrying IL1RN*2 showed higher incidence of R-GH, severe hematuria during the interval stage of gross hematuria, more crescent formation and increase rate of cellular/fibrocellular crescents, higher frequency of segmental glomerular necrosis than that in IgAN patients without IL1RN*2(P0.05). The carriage rate of IL1RN*2 was significantly higher in patients with Cres. IgAN than that in other subgroups of IgAN and normal controls (P0.05). As to HSPN patients, the allele frequency and carriage rate of IL1RN*2 were higher than that in healthy controls, and patients carrying IL1RN*2 also showed more crescent formation and increase rate of cellular/fibrocellular crescents, higher frequency of segmental glomerular necrosis than that in patients without IL1RN*2(P0.05). However, MPA patients did not share the congenerous IL-1ra gene polymorphism. In addition, there was no statistical difference of the IL1RN*2 carriage rate between Cres.IgAN and HSPN. The IL1RN*2 carriage rate of Cres.IgAN patients was actually close to that of HSPN patients with the rates of crescents more than 15%. Conclusion:The carriage rate of IL1RN*2 in patients with Cres. IgAN was significantly higher than that in other subgroups of IgAN and normal controls. IL1RN*2 allele was associated with the occurrence of both Cres.IgAN and HSPN, and the carriage rate of IL1RN*2 in Cres.IgAN patients was actually close to that in HSPN patients whose crescents were more than 15%. Our data suggested that IL1RN*2 allele may be a genetic link between Cres. IgA N and HSPN.
What problem does this paper attempt to address?